ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Oncology — Outside U.S. revenue by Year
Oncology — Outside U.S. revenue ($M) ($M)
Eli Lilly Oncology — Outside U.S. revenue: $4,024M in FY2025, up 8.3% from a year earlier. That is the highest of the 10 years on record here.
Latest, FY2025
4,024
Period ended Dec 31, 2025
Change on a year earlier
+8.3%
3,717 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K Note 2.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Oncology — Outside U.S. revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,024 | +8.3% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 3,717 | +29.9% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 2,861 | +16.9% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 2,448 | -9.7% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 2,713 | +7.3% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 2,527 | +26.0% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 2,006 | +8.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 1,857 | +5.4% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 1,762 | +0.8% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 1,747 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Oncology — Outside U.S. revenue ($M), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta-oncology-nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.